GSK Drug Partner XenoPort Hit With Stock Drop Action
By Leigh Kamping-Carder ( September 27, 2010, 5:09 PM EDT) -- A XenoPort Inc. shareholder has filed a proposed class action that accuses the biopharmaceutical company of withholding information related to Horizant — a restless leg syndrome drug it was developing with GlaxoSmithKline PLC — that allegedly caused its stock price to plummet....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.